Commodore Capital LP Has $25.01 Million Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Commodore Capital LP cut its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 64.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,000,000 shares of the company’s stock after selling 1,850,000 shares during the period. Centessa Pharmaceuticals accounts for approximately 1.7% of Commodore Capital LP’s investment portfolio, making the stock its 24th biggest holding. Commodore Capital LP’s holdings in Centessa Pharmaceuticals were worth $25,010,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CNTA. Baker BROS. Advisors LP bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $16,775,000. Armistice Capital LLC raised its position in shares of Centessa Pharmaceuticals by 32.3% during the fourth quarter. Armistice Capital LLC now owns 500,000 shares of the company’s stock worth $12,505,000 after purchasing an additional 122,000 shares during the period. Burkehill Global Management LP acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $3,752,000. Braidwell LP bought a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth $54,730,000. Finally, Jain Global LLC grew its position in Centessa Pharmaceuticals by 278.5% in the 4th quarter. Jain Global LLC now owns 915,803 shares of the company’s stock valued at $22,904,000 after purchasing an additional 673,828 shares during the period. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ CNTA opened at $39.87 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $6.17 billion, a PE ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.30 and a one year high of $40.26. The business’s fifty day moving average price is $39.65 and its 200-day moving average price is $31.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CNTA. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their target price for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Truist Financial lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a report on Monday, April 13th. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $41.33.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the sale, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. The trade was a 39.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.